Research progress on risk factors for poor response of ursodeoxycholic acid in primary biliary cholangitis / 中华肝脏病杂志
Chinese Journal of Hepatology
; (12): 73-76, 2019.
Article
in Zh
| WPRIM
| ID: wpr-810373
Responsible library:
WPRO
ABSTRACT
Primary biliary cholangitis (PBC) is an autoimmune-mediated chronic cholestatic liver disease. Ursodeoxycholic acid (UDCA) is a first-line drug approved by the Food and Drug Administration for the treatment of PBC. It can effectively improve serum biochemical indicators, delay histological progress, and prolong the survival of non-transplant patients. However, around 40% of patients with PBC have a poor response to UDCA with a poor outcome. Early identification of patients with poor biochemical responses and timely second-line treatment may alter the course of the disease. This article summarizes the risk factors for the poor response of UDCA in the PBC.
Full text:
1
Index:
WPRIM
Type of study:
Etiology_studies
/
Prognostic_studies
/
Risk_factors_studies
Language:
Zh
Journal:
Chinese Journal of Hepatology
Year:
2019
Type:
Article